Imaging based high content phenotyping is at the heart of insitro’s efforts to rethink drug development. Our goal is to use machine learning to extract disease phenotypes from high throughput, high content, microscopy image datasets of cellular disease model systems and identify connections to clinical disease phenotypes.
As a machine learning engineer with expertise in microscopy image analysis you will develop cutting edge ML approaches to analyze data from multiple microscopy technologies and platforms. You will integrate in vitro imaging data produced at insitro with other data modalities such as transcriptomics and data from large-scale human cohorts to extract insights about disease mechanisms. You will be part of a cross-functional team of life scientists, bioengineers and machine learning scientists to identify therapeutic targets and develop drugs that have high efficacy and low toxicity.
You will be joining an agile and fast growing biotech startup that has long-term stability due to significant funding, but yet is very much in formation. You will have ample opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us, and help make a difference to patients!
Nice to Have
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures.
The company has announced collaborations with Gilead Sciences in the area of NASH (2019) and Bristol Myers Squibb in the area of ALS (2020) and, in mid 2020, completed a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com
Your application was submitted successfully.